Nicotine enhances attentional and working memory aspects of executive function in the prefrontal cortex (PFC) where dopamine plays a major role. Here, we have determined the nicotinic acetylcholine receptor (nAChR) subtypes that can modulate dopamine release in rat PFC using subtype-selective drugs. Nicotine and 5-Iodo-A-85380 (b2* selective) elicited [ 3 H]dopamine release from both PFC and striatal prisms in vitro and dopamine overflow from medial PFC in vivo. Blockade by dihydro-b-erythroidine supports the participation of b2* nAChRs. However, insensitivity of nicotine-evoked [ 3 H]dopamine release to a-conotoxin-MII in PFC prisms suggests no involvement of a6b2* nAChRs, in contrast to the striatum, and this distinction is supported by immunoprecipitation of nAChR subunits from these tissues. The a7 nAChR-selective agonists choline and Compound A also promoted dopamine release from PFC in vitro and in vivo, and their effects were enhanced by the a7 nAChR-selective allosteric potentiator PNU-120596 and blocked by specific antagonists. DNQX and MK801 inhibited [ 3 H]dopamine release evoked by choline and PNU-120596, suggesting crosstalk between a7 nAChRs, glutamate and dopamine in the PFC. In vivo, systemic (but not local) administration of PNU-120596, in the absence of agonist, facilitated dopamine overflow in the medial PFC, consistent with the activation of extracortical a7 nAChRs by endogenous acetylcholine or choline. These data establish that both b2* and a7 nAChRs can modulate dopamine release in the PFC in vitro and in vivo. Through their distinct actions on dopamine release, these nAChR subtypes could contribute to executive function, making them specific therapeutic targets for conditions such as schizophrenia and attention deficit hyperactivity disorder.
Introduction
The prefrontal cortex (PFC) is the site of integration of widespread glutamatergic inputs essential for executive function and goaldirected behaviour. Dopamine is a prominent modulator of PFC executive functions, including working memory and attention (Williams & Goldman-Rakic, 1995; Schultz, 2002; Floresco & Magyar, 2006) . For example, local infusion of a dopamine D1 agonist into the medial PFC (mPFC) of rats increased attentional performance in animals with low baseline levels of accuracy (Granon et al., 2000) . Working memory and attentional performance are also improved by nicotine, in both laboratory animals and humans (Newhouse et al., 2004; Levin et al., 2006; Mansvelder et al., 2006) . The ability of nicotine to increase dopamine release from ascending dopamine neurons (Nisell et al., 1994) offers one mechanism to account for the positive influence of nicotine on executive function.
Nicotine facilitates dopamine release by acting at somatodendritic or presynaptic nicotinic acetylcholine receptors (nAChRs) on mesolimbic and nigrostriatal neurons. nAChRs constitute a family of pentameric ligand-gated cation channels that differ in subunit composition and functional properties (Gotti et al., 2006) . A multiplicity of b2-containing heteromeric nAChRs reside on cell soma and nerve terminals of midbrain dopamine neurons (Klink et al., 2001; Grady et al., 2007) . These can be distinguished into two classes based on the presence or absence of the a6 subunit (a6b2* or a4b2* nAChRs), using the a3 ⁄ a6b2-selective antagonist a-conotoxin MII (aCnTxMII). Presynaptic nAChRs facilitate dopamine release in vitro in the absence of other depolarizing stimuli (Wonnacott, 1997; Grady et al., 2007) , and they may be important for the local integration of endogenous cholinergic signals (Exley & Cragg, 2008) , with a6b2* nAChRs having a dominant role in the nucleus accumbens (Exley et al., 2007) . Homomeric a7 nAChRs are more commonly associated with glutamatergic nerve terminals. Presynaptic a7 nAChRs on glutamate afferents to the ventral tegmental area (VTA; participate in mechanisms of synaptic plasticity (Mansvelder et al., 2002) and influence the probability of burst firing in mesolimbic dopamine neurons, with consequent increases in accumbens dopamine release (Schilstrom et al., 1998) . In the striatum in vitro, dopamine release is influenced locally by a7 nAChRs that are proposed to reside on glutamatergic afferents (Kaiser & Wonnacott, 2000; Barik & Wonnacott, 2006) .
In the PFC, both a4b2* and a7 nAChRs have been implicated in attentional performance and cognition. Nicotine injections into the PFC enhance accuracy in a working memory task (Hahn et al., 2003) . Transgenic mice lacking the a7 nAChR subunit have deficits in attentional and working memory tasks (Young et al., 2004; Fernandes et al., 2006; Hoyle et al., 2006; Young et al., 2007) , whereas a4b2* and a7 nAChR subtype-selective agonists improve working and reference memory in rats (Chan et al., 2007) . However, there is little information on the functional organization of nAChR subtypes within the PFC, especially in relation to mesocortical dopaminergic projections (Mansvelder et al., 2006; Couey et al., 2007) . In the present study we have addressed the modulation of dopamine release in the PFC by nAChRs in vitro and in vivo, using subtype-selective agonists in conjunction with selective antagonists. We show that both a7and b2-containing nAChRs can influence dopamine release.
Materials and methods

Animals
Male Sprague-Dawley rats (200-300 g, in vitro assays; 250-300 g, microdialysis; Charles River Laboratories and University of Bath Animal House breeding colony) were used. Prior to surgery, rats were housed in groups of four per cage in a temperature-and humiditycontrolled environment with free access to food and water. Rats were kept on a 12-h light: dark cycle, with lights on at 07.00 h. All experiments were carried out within the guidelines of the United Kingdom Animals (Scientific Procedures) Act 1986. [7, H]Dopamine (43 Ci ⁄ mmol) was purchased from GE Healthcare (Little Chalfont, Buckinghamshire, UK). 5-Iodo-3-(2(S)-azetidinylmethoxy)pyridine dihydrochloride (5-Iodo-A-85380, 5-I-A-85380), methyllycaconitine (MLA), nisoxetine hydrochloride, GBR12909 dihydrochloride, 6,7-dinitroquinoxaline-2,3-dione (DNQX) and a-CnTxMII were obtained from Tocris Cookson (Bristol, UK). ())-Nicotine tartrate, dihydro-b-erythroidine (DHbE), chlorisondamine, mecamylamine, (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK801), pargyline hydrochloride, choline tartrate, ascorbic acid and nomifensine maleate were purchased from Sigma-Aldrich (Poole, Dorset, UK). (R)-N-(1-azabicyclo[2.2.2] oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) (Compound A) and 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-120596) were synthesized by GSK (Harlow, UK). a-Bungaro-toxin (a-Bgt) was acquired from Molecular Probes (Pourt Gebaow, the Netherlands). Optiphase Supermix was obtained from Perkin Elmer NV ⁄ SA (Zaventem, Belgium) and Optiphase 'Safe' was acquired from Fisher Chemicals (Loughborough, Leicestershire, UK). All other chemicals were of analytical grade and obtained from Sigma-Aldrich (Poole, Dorset, UK) . For in vivo studies, PNU-120596 was dissolved in dimethylsulphoxide (DMSO) to 100 mm and diluted in artificial cerebrospinal fluid (aCSF) to give the desired final concentration for local administration via the microdialysis probe. All other drugs for administration via this route were dissolved directly in aCSF (pH adjusted to 7.4). For systemic injections, PNU-120596 and chlorisondamine were dissolved in 5% DMSO in saline, and MLA was dissolved directly in saline.
Drugs
[ 3 H]Dopamine release in vitro
A 96-well filter plate method was used (Anderson et al., 2000; Barik & Wonnacott, 2006) . Briefly, two rats were killed by cervical dislocation, and the striatum (160 mg) and PFC (110 mg) were dissected. PFC was defined as 3 mm from anterior, 4 mm from bregma and 1 mm from corpus callosum. Tissue was chopped using a McIlwain tissue chopper to give 150 lm prisms. The prisms were washed in Kreb's buffer [KB; (in mm): NaCl, 118; KCl, 2.4; CaCl 2 , 2.4; KH 2 PO 4 , 1.2; MgSO 4 AE7H 2 O, 1.2; NaHCO 3 , 25; d-glucose, 10; ascorbic acid, 1; pH 7.4 containing 10 lm pargyline) and incubated with 50 nm [ 3 H]dopamine for 30 min at 37°C. After four washes with KB containing 0.5 lm nomifensine, the prisms were distributed between the wells of a 96-well filter plate and incubated with or without antagonist or PNU-120596 in KB (70 lL) at 37°C for up to 20 min. Buffer was removed by filtration and replaced with 70 lL KB containing agonist and ⁄ or antagonist or PNU-120596. After a further 5 min at 37°C, buffer containing released [ 3 H]dopamine was collected by filtration. Treatments with DNQX and MK801 were conducted in Mg 2+ -free KB. Tritium released into the filtrate and that remaining on the filters was determined by scintillation counting in a Wallac 1450 Microbeta Trilux (Perkin Elmer Wallac, Turku, Finland).
Data analysis
Fractional release of [ 3 H]dopamine was calculated as the percent of total radioactivity present before stimulation. Typical basal release of [ 3 H]dopamine in the absence of agonist was 14.0 ± 0.5% (n = 5) for striatal prisms and 13.0 ± 0.7% (n = 4) for PFC prisms; basal values were subtracted from agonist-evoked responses before constructing concentration-response curves. Statistical significance was assessed using unpaired Student's t-test, or one-or two-way anovas with Tukey's post hoc test for multiple comparisons, as specified in the figure legends.
[ 3 H]Dopamine uptake
Striatal and PFC prisms were pre-incubated for 10 min in KB alone, 0.5 lm nomifensine, 50 nm GBR12909 or 1 lm nisoxetine, at 37°C or 4°C. Then [ 3 H]dopamine (100 lL; final concentration 50 nm) was added and samples were incubated with intermittent shaking for 5 or 30 min. Tissue was collected by filtration through GF ⁄ C glass fibre filters using a Millipore manifold system and washed three times with 3 mL ice-cold KB. Samples were counted in a Packard Tri-carb 1600 liquid scintillation counter with 46% counting efficiency (Perkin Elmer Life and Analytical Sciences).
Immunoprecipitation nAChR subunits were quantitated by immunoprecipitation using subunit-specific polyclonal antibodies raised in rabbits and generated against peptides corresponding to the C-terminus or major intracellular loop of rat nAChR subunits (Champtiaux et al., 2003; Gotti et al., 2005) . Rat striatal and PFC tissue was extracted using 2% Triton X-100 in (in mm): Tris-HCl, 50, pH 7.0; NaCl, 120; KCl, 5; MgCl 2 , 1; CaCl 2 , 2.5; phenylmethylsulphonyl fluoride, 2; containing the protease inhibitors leupeptin, bestatin, pepstatin A and aprotinin, each at 20 lg ⁄ mL (2 h, 4°C). Following preincubation for 2 h with 2 lm aBgt and labelling with 2 nm [ 3 H]epibatidine for 2 h at room temperature, nAChRs were immunoprecipitated by incubating overnight with saturating concentrations of affinity-purified subunitselective antibodies (20-30 lg) and recovered by incubating the samples with anti-IgG-coated beads (Technogenetics, Milan, Italy). For the a2-, a3-, a4-, b2and b4-subunits antibodies directed against the intracytoplasmic loop peptide were used, whereas for the a5-, a6and b3-subunits antibodies directed against both the C-terminal and intracytoplasmic loop peptides were used. Each subunit-specific immunoprecipitate was quantified as a percentage of the total population of [ 3 H]epibatidine-labelled nAChRs precipitated and expressed as femtomoles per mg protein.
Surgery and brain microdialysis
Rats were anaesthetized with ketamine (75 mg ⁄ kg i.p.; Ketaset, Fortdodge Animal Health, Southampton, UK) and medetomidine (0.5 mg ⁄ kg i.p.; Domitor, Orion Pharma, Newbury, UK), and stereotaxically implanted with homemade unilateral microdialysis probes with a 4-mm active dialysis membrane (polyacrylonitrile ⁄ sodium methalyl sulphonate copolymer, internal diameter 0.22 mm, external diameter 0.31 mm; AN 69, Hospal, Bologna, Italy). The co-ordinates of the implantation were A ⁄ P + 3.3, L ⁄ M + 0.8 and V ⁄ D )5.0 from bregma and dura with the incisor bar kept at )3.3 mm (Paxinos & Watson, 1986) . Buprenorphine (0.05 mg ⁄ kg s.c.; Vetergesic, Alstoe Animal Health, Sheriff Hutton, York, UK) was administered as an analgesic and anaesthesia was reversed with atipamezole (1 mg ⁄ kg ⁄ s.c.; Antisedan, Orion Pharma, UK). Microdialysis was performed the next day. Probes were perfused with aCSF at 2 lL ⁄ min (in mm: NaCl, 150; KCl, 3; CaCl 2 , 1.4; MgCl 2 , 0.8, pH 7.4), and 15-min fractions were collected. Following 4 h equilibration, baseline samples were collected for 90 min. Agonist (or vehicle control) in aCSF was then perfused for 30 min. Antagonists or modulators given locally were perfused continuously for 30 min before perfusion of agonist and was stimulated by increasing concentrations of nicotine (0.01-100 lm) and measured by filtration. Fractional release was determined as a proportion of [ 3 H]dopamine present in the tissue at the time of stimulation, as described in the Materials and methods. Responses to nicotine were determined in the presence (open symbols) or absence (closed symbols) of 120 nm a-conotoxin MII (aCnTxMII) in striatal (A) and PFC (B) prisms. Basal release in the absence of agonist has been subtracted. Note the different y-axis scales for the two tissues. Data points were fitted to a single site Hill equation. Data points represent mean ± SEM, n = 4, *significantly different from response in the absence of aCnTxMII, P < 0.05, two-way anova, Tukey's post hoc test. (C) nAChR subunits were immunoprecipitated using specific antibodies from Triton X-100-permeabilized rat striatal (filled bars) or PFC tissue (open bars) labelled with [ 3 H]epibatidine as described in the Materials and methods. The results are expressed as fmol ⁄ mg protein by reference to the specific radioactivity of the ligand. Each bar represents mean ± SEM, n = 3 independent experiments, *significantly different from striatum, P < 0.05, unpaired two-tailed Student's t-test. **Significantly different from striatum, P < 0.01, unpaired two-tailed Student's t-test.
remained in the aCSF until the end of the experiment. The vehicle for PNU-120596 was 0.01% DMSO: at higher concentrations (0.1%) DMSO itself increased dopamine overflow. The same syringe changes were carried out on all animals, irrespective of the need to change drug perfusion, so that this manipulation was common to all experiments. For systemic administration of antagonists, chlorisondamine (10 mg ⁄ kg i.p.) was given 7 days before surgery, whereas MLA (3 mg ⁄ kg i.p.) was injected 45 min before perfusion of agonist. The modulator PNU-120596 (1 mg ⁄ kg i.p.) was injected at the time when local perfusion of modulator would otherwise commence. At the end of the experiment, the rat was given an overdose of pentobarbitone (Euthatol, Merial, UK), and the brain was removed and fixed with 4% paraformaldehyde. Coronal sections (40 lm thick) were made, and microdialysis probe placement verified.
Dopamine analysis
Dopamine in the microdialysate samples was quantified by reversephase, ion-pair high-pressure liquid chromatography coupled with electrochemical detection (HPLC-ECD). A Jasco (PU-980) HPLC pump was used in conjunction with an ECD (DECADE, Antec, Leiden, the Netherlands) with an amperometric VT-03 cell set at 650 mV. Compounds were separated on a reverse-phase column (HAISIL 100 C-18, 3 lm, 100 · 2.1 mm; Higgins Analytical, Mountain View, California, USA). The mobile phase consisted of a mixture of 100 mmol ⁄ L sodium acetate, adjusted to pH 4.0 with perchloric acid, 0.7 mmol ⁄ L octanesulphonic acid, 1 mmol ⁄ L Na 2 EDTA and 120 mL methanol ⁄ L HPLC grade water at a flow rate of 0.2 mL ⁄ min. The detection limit was about 1 fmol per 30 lL. The mean basal extracellular level of dialysate dopamine from the mPFC samples was 5.02 ± 0.35 fmoles (n = 161). These data have not been corrected for recovery across the microdialysis membrane.
In vitro recovery of dopamine
The in vitro recovery of dopamine across the microdialysis membrane was determined in randomly selected microdialysis probes. The microdialysis probes were placed in a standard solution of dopamine (10 )8 -10 )6 m) and flushed with aCSF at 2 lL ⁄ min for 5 min. Levels of dopamine entering the microdialysate were determined. Recoveries were calculated from the concentration of dopamine in the microdialysate as a percentage of the concentration in the standard solution. The recovery of dopamine across a 4-mm active microdialysis membrane was 18.3 ± 1.31% (n = 20).
Data analysis
Values for in vivo dopamine overflow are shown as mean ± SEM. The mean dopamine concentration of the initial three baseline samples was taken as 100% (<15% variation). Values for subsequent samples were calculated as a percentage of basal release. Data were analysed using two-way anova for repeated measurements (time · treatment) followed by Bonferroni post hoc test for multiple comparisons. Where necessary, data within the same curve were analysed by one-way anova for repeated measures followed by Newman-Keuls post hoc test. Peak areas (area under the curve) for multiple groups were compared using one-way anova with Newman-Keuls post hoc test. Unpaired two-tailed t-test was used for comparing peak areas between two groups.
Results
[ 3 H]Dopamine release from PFC prisms in vitro is modulated by b2-containing nAChRs that do not include a6-subunits Nicotine has been shown previously to elicit [ 3 H]dopamine release from cortical synaptosomes and prisms by interacting with local nAChRs (Whiteaker et al., 1995; Cao et al., 2005) . Here, we have used an in vitro 96-well plate filter assay Barik & Wonnacott, 2006) to assess the subtypes of nAChR that modulate release from PFC prisms loaded with [ 3 H]dopamine; striatal prisms were assayed in parallel for comparison. Loading experiments in the presence of different selective uptake inhibitors confirmed that [ 3 H]dopamine is predominantly accumulated by dopamine terminals in both the striatum and PFC (data not shown).
Nicotine (0.01-100 lm) induced the concentration-dependent release of [ 3 H]dopamine, with similar potencies in striatal and PFC prisms (striatum pEC 50 )6.8 ± 0.3; PFC pEC 50 )6.2 ± 0.3; Fig. 1A  and B ). However, nicotine-induced fractional release in striatal prisms was 2.5 ± 0.3 times more efficacious than in PFC prisms. In both tissues, responses to 10 lm nicotine were attenuated by mecamylamine (30 lm), and abolished by DHbE (30 lm) and chlorisondamine (100 lm; Table 1 ).
The b2-selective agonist 5-I-A-85380 (0.001-1 lm; Mukhin et al., 2000; Mogg et al., 2004 ) also increased [ 3 H]dopamine release ( Fig. 2 ) with comparable potency in both regions (striatum pEC 50 )7.9 ± 0.2; PFC pEC 50 )8.1 ± 0.3; Fig. 2 ). As seen with nicotine, the maximum response to 5-I-A-85380 was greater in the striatum than the PFC. 5-I-A-85380-evoked [ 3 H]dopamine release was inhibited by DHbE that shifted the dose-response curve for 5-I-A-85380 to the right (F 3,12 = 3.64; P < 0.05 for striatum; F 3,12 = 3.86; P < 0.05 for PFC; Fig. 2) .
A maximally effective concentration of the a3 ⁄ a6b2* nAChR antagonist aCnTxMII (120 nm) partially inhibited nicotine-evoked [ 3 H]dopamine release in the striatum by up to 29.5 ± 2.2% (F 3,8 = 4.32; P < 0.05; Fig. 1A ), in agreement with previous studies (Kulak et al., 1997; Kaiser et al., 1998; Grady et al., 2007) . In (Gotti et al., 2005) . In the PFC, in contrast to levels in the striatum, b3-containing nAChRs were not detectable and the percentage of a6-containing nAChRs (2.6% of total [ 3 H]epibatidine-labelled nAChRs present in the tissue extract) is lower than the threshold of the immunoprecipitation technique (5%; Fig. 1C ). The expression of other nAChR subunits was similar between the two regions, except for a significantly lower level of the a5 nAChR subunit in PFC (Fig. 1C) . The level of the a3-subunit in PFC was low, but its expression is specific and significantly higher (P < 0.05) than in the striatum, as determined in parallel experiments using the same antibodies.
a7 nAChRs indirectly modulate [ 3 H]dopamine release via ionotropic glutamate receptors
In striatal slices (but not synaptosomes) a portion of anatoxina-evoked [ 3 H]dopamine release could be blocked by aBgt, consistent with an indirect effect of a7 nAChRs (Kaiser & Wonnacott, 2000) . In the present experiments, aBgt (40 nm) did not decrease [ 3 H]dopamine release evoked by nicotine at any concentration tested (10 nm-100 lm) in either striatum or PFC prisms (Fig. 3) . However, co-application of the specific a7 nAChR-positive allosteric modulator PNU-120596 (10 lm; Hurst et al., 2005) with nicotine further increased [ 3 H]dopamine release in response to the higher concentrations of nicotine in both striatal and PFC prisms. This corresponds to an increase in evoked release of 40% (after subtraction of basal levels) in both regions. In the presence of aBgt, the enhanced release in the presence of PNU-120596 was reduced to the level of the response to nicotine alone. The ability of a7 nAChRs in both striatum and PFC to influence [ 3 H]dopamine release was confirmed using an a7 nAChR-selective agonist. Choline (3 mm) significantly increased the fractional release of [ 3 H]dopamine from both regions to a similar extent, and this was inhibited by a-Bgt (Table 1) . PNU-120596 (10 lm) further augmented responses to 3 mm choline (Fig. 4A) , and the responses were completely blocked by a-Bgt (Table 1) .
[ 3 H]Dopamine release elicited by choline plus PNU-120596 was partially blocked in the presence of ionotropic glutamate receptor antagonists (tested in Mg 2+ -free conditions; see Materials and methods). The a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) ⁄ kainate receptor antagonist DNQX (200 lm) significantly reduced [ 3 H]dopamine release by 59.8 ± 3.2% (striatum) and 69 ± 4.2% (PFC); the N-methyl-d-aspartate (NMDA) receptor antagonist MK801 (5 lm) inhibited [ 3 H]dopamine release by 40.3 ± 3.6% (striatum) and 58.7 ± 4.1% (PFC; Fig. 4B ). The effects of DNQX and MK801 were additive when co-applied with choline and PNU-120596: under this condition the amount of [ 3 H]dopamine release did not differ significantly from basal release (Fig. 4B) .
To determine if glutamate receptors also mediate [ 3 H]dopamine release evoked by activation of b2* nAChRs, we used 1 lm nicotine, a concentration not blocked by aBgt (Fig. 3) , to selectively activate b2* nAChRs. Nicotine-evoked [ 3 H]dopamine release in both striatum and PFC was unaffected by the presence of DNQX and ⁄ or MK801 (Fig. 4C) . Thus, a7 nAChRs can influence dopamine release in the striatum and PFC, via the release of glutamate, whereas b2-containing nAChRs promote [ 3 H]dopamine release without the intervention of ionotropic glutamate receptors.
Nicotine-evoked dopamine overflow in mPFC
To determine if a7 and b2* nAChRs modulate endogenous dopamine release in mPFC we used in vivo microdialysis in conscious freely moving rats. Local perfusion of nicotine (30 lm-3 mm) into the mPFC, delivered via the microdialysis probe by retrograde dialysis for 30 min, produced a concentration-dependent increase in extracellular dopamine levels that rapidly returned to basal levels after removal of nicotine from the perfusate (Fig. 5A) . The highest concentration of nicotine (3 mm) produced a large increase in dopamine levels (F 9,20 = 12.1; P < 0.05) compared with the response to 1 mm nicotine (F 5,30 = 3.88; P < 0.05). The increase in extracellular dopamine in response to 1 mm nicotine was blocked by prior systemic administration of the long-acting non-competitive nAChR antagonist chlorisondamine (10 mg ⁄ kg i.p.; F 9,30 = 7.35; P < 0.05), administered 7 days before microdialysis. Chlorisondamine alone did not affect basal values, in comparison to vehicle-treated controls (4.64 ± 0.36 fmoles and 5.00 ± 0.46 fmoles, respectively; Fig. 5B ). The response to 1 mm nicotine was also completely blocked by local administration of chlorisondamine (100 lm; F 8,27 = 6.34; P < 0.05) via the microdialysis probe ( Fig. 5C) , confirming that the effect of nicotine was mediated by nAChRs in the mPFC, consistent with the data from in vitro prisms.
To address the subtypes of nAChR responsible for nicotine-evoked dopamine overflow, the subtype-selective antagonists DHbE and MLA were locally applied, before and during the delivery of 1 mm nicotine. DHbE (10 lm) significantly decreased the response to nicotine (F 8,27 = 11.1; P < 0.05), whereas the a7 nAChR-selective antagonist MLA (100 lm) failed to affect the nicotine-induced increase in extracellular dopamine (Fig. 5C ).
The effect of nAChR subtype-selective agonists on dopamine overflow in the mPFC
Local perfusion of 5-I-A-85380 (100 lm and 1 mm) increased extracellular dopamine overflow above basal ( Fig. 6 ; F 13,56 = 17.7; P < 0.05; F 13,56 = 23.4; P < 0.05, respectively). The two concentrations tested elicited similar responses, comparable in magnitude to that elicited by 3 mm nicotine (Fig. 5A ). The increase in dopamine overflow in response to 100 lm 5-I-A-85380 was abolished by the continuous co-perfusion of DHbE, consistent with 5-I-A-85380 acting at b2* nAChRs ( Fig. 6 ; F 13,56 = 7.06; P < 0.05).
To examine if activation of a7 nAChRs can elicit an increase in dopamine overflow, we took advantage of the novel a7 nAChRselective agonist Compound A (Cilia et al., 2005; Dickinson et al., 2008) . Local perfusion of Compound A (100 lm and 1 mm) into the mPFC produced a concentration-dependent increase in extracellular dopamine levels above basal ( Fig. 7A and B ; F 13,42 = 5.93; P < 0.05; F 13,112 = 4.85; P < 0.05, respectively); the response to the higher concentration tested was markedly lower than the maximum responses to nicotine and 5-I-A-85380. Increases in dopamine overflow in response to 100 lm or 1 mm Compound A were attenuated by administration of MLA, either systemically (3 mg ⁄ kg i.p.; Fig. 7A ; F 13,42 = 5.53; P < 0.05) or locally (100 lm; Fig. 7B ; F 13,112 = 11.6; P < 0.05).
To substantiate a role for a7 nAChRs in the modulation of dopamine release in the mPFC, we examined the effect of PNU-120596. Co-perfusion of PNU-120596 (10 lm) with a subthreshold concentration of Compound A (10 lm) resulted in a significant increase in dopamine overflow, comparable to the response to 1 mm nicotine ( Fig. 8A ; F 11,48 = 6.77; P < 0.05). Local perfusion of PNU-120596 (10 lm) or vehicle (0.01% DMSO) in the absence of exogenous agonist did not increase dopamine overflow above basal levels. However, systemic administration of PNU-120596 (1 mg ⁄ kg s.c.) in the absence of agonist did elicit a rapid increase in dopamine overflow in the mPFC that declined gradually over the next hour ( Fig. 8B ; F 14,90 = 12.3; P < 0.05). This effect was attenuated by prior systemic injection of MLA (3 mg ⁄ kg i.p.; F 14,45 = 8.49; P < 0.05).
Discussion
We have used an in vitro release assay and in vivo microdialysis to characterize nAChR-evoked dopamine release in the rat PFC. Nicotine and 5-I-A-85380 promoted DHbE-sensitive dopamine release in vitro and in vivo, indicative of the participation of local b2-containing nAChRs. Nicotine-evoked [ 3 H]dopamine release from PFC prisms was insensitive to aCnTxMII, in contrast to release from striatal tissue; the absence of a6-containing nAChRs in the PFC is supported by immunoprecipitation experiments. The ability of a7 nAChRs in the PFC to facilitate dopamine release was demonstrated using choline in vitro and Compound A, delivered via the microdialysis probe, in vivo. These responses were blocked by a7 nAChR-selective antagonists and potentiated by PNU-120596. Ionotropic glutamate receptor antagonists DNQX and MK801 blocked the release of [ 3 H]dopamine from PFC prisms stimulated by choline plus PNU-120596, consistent with a7 nAChRs acting indirectly by promoting glutamate release, as observed in the striatum. Finally, the differential effects of systemic and locally applied PNU-120596 in vivo suggest that in the presence of the potentiator extra-cortical cholinergic tone can activate a7 nAChRs to promote dopamine overflow in the mPFC.
Dopamine in the PFC plays a significant neuromodulatory role in aspects of executive function and goal-directed behaviours, and dopamine levels are critical for optimal performance (Schultz, 2002; Floresco & Magyar, 2006) . Prefrontal dopaminergic dysfunction contributes to neuropysychiatric conditions, including schizophrenia (Toda & Abi-Dargham, 2007) and attention deficit hyperactivity disorder (Levy, 2008) . nAChR ligands have been advocated as therapeutic candidates for such conditions (Jensen et al., 2005; Mazurov et al., 2006; Arneric et al., 2007) . In view of the welldocumented ability of various nAChR subtypes to influence striatal and accumbens dopamine release (Klink et al., 2001; Grady et al., 2007) , detailed examination of the nicotinic modulation of dopamine release in the PFC was warranted. By exploiting both in vitro and in vivo assays we have generated a comprehensive picture of the diversity and interplay of local nAChR subtypes capable of influencing dopamine release in the rat PFC.
Heteromeric b2-containing nAChR subtypes modulate dopamine release in the PFC; comparison with striatum Nicotine-evoked [ 3 H]dopamine release from PFC prisms and dopamine overflow from the mPFC in vivo was concentration-dependent and nAChR-dependent, with complete blockade produced by chlorisondamine. Sensitivity to DHbE supports the involvement of b2-containing nAChRs, and this is reinforced by the ability of 5-I-A-85380 to elicit DHbE-sensitive dopamine release in vitro and in vivo (Mukhin et al., 2000; Mogg et al., 2004) .
Dopaminergic projections to the rodent striatum contain a variety of b2-containing nAChRs that include different combinations of a4-, a5-, a6and b3-subunits . Those with an a6b2 interface can be discriminated by blockade with aCnTxMII (Champtiaux et al., 2003; Salminen et al., 2007) and account for about 30% of the total response to nicotine in rat striatal prisms ( Fig. 1 ; Kaiser et al., 1998; Cao et al., 2005) . The notable difference between striatal and PFC prisms is the absence of an aCnTxMII-sensitive component of nicotine-evoked [ 3 H]dopamine release in PFC ( Fig. 1) : this distinction is in agreement with a previous study (Cao et al., 2005) . The absence of a6-containing nAChRs from the PFC was preincubated with or without 10 lm PNU-120596 for 10 min prior to stimulation with 3 mm choline in the presence or absence of PNU-120596 for 5 min. (B) Tissue was preincubated with 10 lm PNU-120596 with or without antagonist for 10 min prior to stimulation with 3 mm choline plus PNU-120596 in the presence or absence of 6,7-dinitroquinoxaline-2, 3-dione (DNQX; 200 lm) and ⁄ or (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK801; 5 lm) for 5 min. (C) Tissue was preincubated with or without antagonist for 10 min prior to stimulation with 1 lm nicotine in the presence or absence of DNQX (200 lm) and ⁄ or MK801 (5 lm) for 5 min. Bars show mean ± SEM. n = 5, *significantly different from buffer control (A) or agonist-evoked response (B), P < 0.05; # P < 0.05, significant effect of PNU-120596, for both striatum and PFC, one-way anova with post hoc Tukey's test. corroborated by immunoprecipitation experiments. Although a small amount of a3 nAChR subunit was detected in the PFC, and a3b2containing nAChRs are sensitive to aCnTxMII (Cartier et al., 1996) , the failure of this toxin to block nicotine-evoked [ 3 H]dopamine release from PFC prisms suggests that a3-subunits are associated with nAChRs that do not influence dopamine release.
Interestingly, in PFC prisms the efficacy of [ 3 H]dopamine release in response to nicotine and 5-I-A-85380 was about 40% of the responses in striatal prisms; a lower response in PFC was also noted by Cao et al., (2005) . As release is calculated as a fraction of the total [ 3 H]dopamine in the tissue, this is not a reflection of the lower density of dopaminergic terminals in the PFC; nor is the lower efficacy of release due to intrinsic differences in presynaptic dopaminergic mechanisms because a7 nAChR stimulation provokes fractional release of comparable magnitude in the two tissues. One interpretation is that a smaller proportion of prefrontal dopamine terminals bear nAChRs, compared with the striatum. Alternatively, differences in the density of nAChRs or their coupling to exocytosis could influence the magnitude of [ 3 H]dopamine release. The absence of high-affinity a6b2* nAChRs from PFC dopamine terminals could be a significant factor.
Two recent studies have provided evidence for a6b2* nAChRs making a greater functional contribution in the mesolimbic system (with respect to a6*-mediated currents in VTA neurons and dopamine release in the ventral striatum ⁄ nucleus accumbens core) than in the nigrostriatal system (Drenan et al., 2008; Exley & Cragg, 2008) . This requires that mesolimbic and mesocortical neurons projecting to the nucleus accumbens and PFC, respectively, must differ in expression of the a6-subunit, or assembly of a6-containing nAChRs, or trafficking of those nAChRs to functionally effective presynaptic destinations in the terminal field. Single-cell polymerase chain reaction analysis indicates that about 15% of dopaminergic neurons in the rat VTA and substantia nigra do not express a6 mRNA (Klink et al., 2001) ; it is possible that these neurons include a population that projects to the PFC.
Although aCnTxMII was not applied in vivo in the present study, due to its large size and limited availability, the correspondence between the pharmacology of the nicotinic modulation of dopamine release in vitro and in vivo with respect to other drugs, coupled with the data from immunoprecipitation assays, encourage the assumption that a6b2* nAChRs do not contribute to dopamine release in the mPFC in vivo. Fig. 5 . Nicotine-evoked dopamine overflow in the mPFC in vivo. Rats were implanted unilaterally with a microdialysis probe in the mPFC, as described in the Materials and methods; 15-min (30-lL) serial fractions were collected and dopamine was quantified using HPLC-ECD. (A) Concentration-dependence of nicotine-evoked dopamine overflow was determined, after collection of threefour stable baseline samples, by local infusion of nicotine (30 lm-3 mm) or aCSF (vehicle) by reverse dialysis for 30 min (horizontal bar). *P < 0.05, significant effect of nicotine vs vehicle by two-way repeated-measures anova with Bonferroni post hoc test. (B) Antagonism of nicotine-evoked dopamine overflow by systemic chlorisondamine (CHL). Rats received CHL (10 mg ⁄ kg) or vehicle s.c. 7 days prior to microdialysis. After collection of three or four stable baseline samples, nicotine (1 mm) or aCSF was given locally by reverse dialysis for 30 min (horizontal bar). *P < 0.05, significant effect of nicotine vs. vehicle, # P < 0.05, significant effect of CHL on nicotine-evoked dopamine overflow, two-way repeated-measures anova with Bonferroni post hoc test. (C) Antagonism of nicotine-evoked dopamine overflow by locally applied antagonists. Nicotine (1 mm)-evoked dopamine overflow was determined in the presence and absence of CHL (100 lm), dihydro-b-erythroidine (DHbE; 10 lm) or methyllycaconitine (MLA; 100 lm). Antagonist was delivered by reverse dialysis 30 min before administration of nicotine (1 mm) for 30 min (short horizontal bar) and was maintained in the aCSF throughout the remainder of the experiment (long horizontal bar). *P < 0.05, significant effect of nicotine vs. vehicle, # P < 0.05, significant effect of antagonists on nicotineevoked dopamine overflow, two-way repeated-measures anova with Bonferroni post hoc test. Values are the mean ± SEM, n = 4-6. Insets: Dopamine overflow measured as area under the curve. *P < 0.01 vs. vehicle, # P < 0.05 vs. nicotine, one-way anova with Newman-Keuls test.
a7 nAChRs influence dopamine release in the PFC Although some 40% of rat dopaminergic neurons in the VTA express the a7 nAChR subunit and respond to choline (Klink et al., 2001) , there is little evidence that a7 nAChRs are trafficked to the terminals: [ 3 H]dopamine release from striatal synaptosomes is insensitive to a7 nAChR antagonists (Mogg et al., 2002) and unaffected by deletion of the a7 gene (Salminen et al., 2004) . However, in striatal slices, a portion of [ 3 H]dopamine release evoked by higher concentrations of the broad-spectrum nAChR agonist anatoxin-a could be blocked by aBgt, implicating a contribution from a7 nAChRs in more integrated tissue preparations (Kaiser & Wonnacott, 2000) . Here we used a7 nAChR-specific agonists, with and without the a7 nAChR-selective positive allosteric modulator PNU-120596, to activate this component. In vitro, choline evoked a similar proportion of [ 3 H]dopamine release from both striatal and PFC prisms, and this was enhanced by PNU-120596 and inhibited by aBgt, confirming the involvement of a7 nAChRs. This is also supported by the absence of choline-evoked [ 3 H]dopamine release from striatal prisms from a7 nAChR knockout mice (Quarta et al., 2008) and the sensitivity of choline-induced [ 3 H]dopamine release to the novel a7-selective antagonist a-conotoxin ARIB[V11L, V16D] in the striatum (Innocent et al., 2008) . Although nicotine-evoked [ 3 H]dopamine release was insensitive to aBgt in agreement with Cao et al., (2005) , the addition of PNU-120596 did elicit an aBgt-sensitive increment in release. This suggests that the allosteric potentiator can unmask a subthreshold interaction of nicotine with a7 nAChRs, possibly by reversing or attenuating nicotinemediated receptor desensitization (Hurst et al., 2005) .
In agreement with the in vitro results, local delivery of the a7 nAChR-selective agonist Compound A (Cilia et al., 2005; Dickinson et al., 2008) into the mPFC in vivo evoked dopamine overflow that was blocked by local or systemic administration of MLA, whereas nicotine-evoked dopamine overflow was insensitive to MLA. PNU-120596, in conjunction with a subthreshold concentration of Compound A, substantially increased dopamine overflow. In addition to amplifying or unmasking a7 nAChR responses to exogenous agonist, positive allosteric modulators have the potential to augment the effects of endogenous agonist. This is particularly the case for PNU-120596 because it reduces a7 nAChR desensitization (Hurst et al., 2005) . Therefore in the continuous presence of agonist it can convert a desensitized nAChR to a conducting state Young et al., 2008) . Hence it is noteworthy that systemic administration of PNU-120596 alone provoked a significant increase in dopamine overflow in the mPFC, and this response was attenuated by MLA. In contrast, delivery of PNU-120596 directly into the mPFC had no effect in the absence of agonist, suggesting that cholinergic tone within the mPFC itself is insufficient to activate a7 nAChRs in the presence of PNU-120596. However, increases in cholinergic activity in the PFC that accompany attention-related tasks should be boosted by PNU-120596. Extra-cortically, it appears that adequate acetylcholine or choline is present in the quiescent animal for the positive modulator to elicit a response, but the site of action of PNU-120596 is a matter of speculation. One candidate region is the VTA where activation of presynaptic a7 nAChRs on glutamate afferents and dopaminergic cell bodies (Mansvelder & McGehee, 2000; Klink et al., 2001; , in response to cholinergic tone from the pontine nuclei (Maskos, 2007; Mena-Segovia et al., 2008) , could drive midbrain dopamine neurons to increase dopamine release in the terminal fields.
Behaviourally, systemic administration of PNU-120596 alone has been reported to reverse an amphetamine-induced auditory gating deficit (Hurst et al., 2005) , consistent with an enhancement of intrinsic cholinergic signalling. Other a7 nAChR-selective positive allosteric modulators have produced cognitive enhancement and improvement in working memory (Ng et al., 2007; Timmermann et al., 2007) , effects that could encompass a PFC component consistent with the a7 nAChR-dependent increase in dopamine overflow reported here.
Neurotransmitter crosstalk: glutamate-dopamine interactions
Interactions between dopamine and glutamate systems in the PFC are critical for its integrated functioning, requiring coincident activation of both systems (Jay, 2003) . In agreement with our previous report for striatal slices (Kaiser & Wonnacott, 2000) , [ 3 H]dopamine release evoked by activation of a7 nAChRs is blocked by ionotropic glutamate receptor antagonists in PFC prisms, suggesting that a7 nAChRs reside on glutamate terminals. This is consistent with the presynaptic localization of a7 nAChRs on glutamatergic afferents in various brain regions including the VTA (Mansvelder & McGehee, 2000) . We were unable to explore this relationship in vivo because administration of glutamate receptor antagonists via the microdialysis probe increased dopamine release in the absence of any stimulus, consistent with other reports that ionotropic glutamate receptors exert an inhibitory influence on dopamine release in the PFC (Del Arco & Mora, 2005) . However, nicotine increases glutamate release from thalamo-cortical afferents to the prelimbic area of the PFC in vivo (Gioanni et al., 1999) and layer V of the PFC in vitro (Lambe et al., 2003) . b2* nAChRs appear to underlie these responses, whereas both b2* and a7 nAChR-selective agonists increase excitatory amino acid release from PFC synaptosomes (Dickinson et al., 2008) , and both subtypes have been proposed to reside on glutamatergic afferents that modulate cholinergic function in the PFC . In the present study we found no evidence for any contribution from b2* nAChRs to the indirect modulation of [ 3 H]dopamine release: responses to a low concentration of nicotine were insensitive to both aBgt and glutamate receptor antagonists (but were blocked by DHbE). This suggests that a7 and b2* nAChRs are segregated to distinct populations of glutamatergic terminals and only those bearing a7 nAChRs are strategically localized to influence dopamine release.
Whereas the microarchitecture of the striatum is relatively uniform and well defined (Smith & Bolam, 1990) , such that spillover of released glutamate could act on adjacent dopaminergic boutons, the anatomical relationship between these transmitter systems in the PFC is more complex. Dopamine inputs synapse onto pyramidal neurons, as well as c-aminobutyric acid (GABA)ergic interneurons, and modulate pyramidal cell excitability (Jay, 2003; Tseng & O'Donnell, 2004; Del Arco & Mora, 2005) ; collaterals from these neurons or glutamatergic afferents may bear a7 nAChRs. The close apposition of dopamine and glutamate terminals in the PFC, seen in some morphological studies, would facilitate reciprocal interactions between these systems (see Del Arco & Mora, 2005) . We suggest that this interdependence can be further modulated by a7 nAChRs associated with glutamate terminals.
The ability of b2-containing and a7 nAChRs to modulate dopamine release and dopamine-glutamate interactions in the PFC are likely to Rats were implanted unilaterally with a microdialysis probe in the mPFC as described in the Materials and methods; 15-min (30-lL) serial fractions were collected and dopamine was quantified using HPLC-ECD. (A) After collection of three stable baseline samples, PNU-120596 or vehicle [0.01% dimethylsulphoxide (DMSO)] was delivered into the mPFC by reverse dialysis 30 min before perfusion of a subthreshold concentration of Compound A (10 lm) for 30 min (short horizontal bar). PNU-120596 or vehicle was maintained in the aCSF throughout the remainder of the experiment (long horizontal bar). *P < 0.05, significant effect of PNU-120596 on Compound Aevoked dopamine overflow, two-way repeated-measures anova with Bonferroni's post hoc test. (B) After collection of four stable baseline samples, PNU-120596 (1 mg ⁄ kg) or vehicle (5% DMSO in saline) was administered systemically. Methyllycaconitine (MLA; 3 mg ⁄ kg) or vehicle (saline) was given systemically 45 min prior to PNU-120596. *P < 0.05, significant effect of PNU vs. vehicle, # P < 0.05, significant effect of MLA on PNU-120596evoked dopamine overflow, two-way repeated-measures anova with Bonferroni's post hoc test. Values are the mean ± SEM, n = 5 per group Insets: Dopamine overflow measured as area under the curve. *P < 0.05 vs. vehicle, # P < 0.01 vs. PNU-120596, one-way anova with Newman-Keuls test.
